163 related articles for article (PubMed ID: 34728182)
1. Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy.
Lupușoru G; Ailincăi I; Sorohan BM; Andronesi A; Achim C; Micu G; Caragheorgheopol A; Manda D; Lupușoru M; Ismail G
Diabetes Res Clin Pract; 2021 Dec; 182():109116. PubMed ID: 34728182
[TBL] [Abstract][Full Text] [Related]
2. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
[TBL] [Abstract][Full Text] [Related]
3. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
[TBL] [Abstract][Full Text] [Related]
4. Differential impact of glomerular and tubule-interstitial histological changes on kidney outcome between non-proteinuric and proteinuric diabetic nephropathy.
Fukata F; Eriguchi M; Tamaki H; Uemura T; Tasaki H; Furuyama R; Nishimoto M; Kosugi T; Tanabe K; Morimoto K; Okamoto K; Matsui M; Samejima KI; Tsuruya K
Clin Exp Nephrol; 2024 Apr; 28(4):282-292. PubMed ID: 38019364
[TBL] [Abstract][Full Text] [Related]
5. THE ASSOCIATION OF SERUM BILIRUBIN ON KIDNEY CLINICOPATHOLOGIC FEATURES AND RENAL OUTCOME IN PATIENTS WITH DIABETIC NEPHROPATHY: A BIOPSY-BASED STUDY.
Wu Y; Zhang J; Wang J; Wang Y; Han Q; Li H; Wang T; Liu F
Endocr Pract; 2019 Jun; 25(6):554-561. PubMed ID: 30865534
[No Abstract] [Full Text] [Related]
6. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.
Kostopoulou E; Kalavrizioti D; Davoulou P; Sinopidis X; Papachristou E; Goumenos DS; Dimitriou G; Spiliotis BE; Papasotiriou M
Eur J Pediatr; 2024 May; 183(5):2383-2389. PubMed ID: 38448612
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications.
Sherif EM; El Maksood AAA; Youssef OI; Salah El-Din NY; Khater OKM
J Diabetes Complications; 2019 Sep; 33(9):628-633. PubMed ID: 31301955
[TBL] [Abstract][Full Text] [Related]
9. Validation of the interstitial fibrosis and tubular atrophy on the new pathological classification in patients with diabetic nephropathy: A single-center study in China.
Zhu X; Xiong X; Yuan S; Xiao L; Fu X; Yang Y; Tang C; He L; Liu F; Sun L
J Diabetes Complications; 2016 Apr; 30(3):537-41. PubMed ID: 26796433
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-β-d-Glucosaminidase, and Urinary β2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy.
Mise K; Hoshino J; Ueno T; Hazue R; Hasegawa J; Sekine A; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Fujii T; Hara S; Ohashi K; Takaichi K; Ubara Y
Clin J Am Soc Nephrol; 2016 Apr; 11(4):593-601. PubMed ID: 26801478
[TBL] [Abstract][Full Text] [Related]
11. Histological Spectrum of Clinical Kidney Disease in Type 2 Diabetes Mellitus Patients with special Reference to nonalbuminuric Diabetic Nephropathy: A Kidney Biopsy-based Study.
Prakash J; Patel PS; Iqbal M; Sharma SS; Singh S; Agrawal NK; Singh U
J Assoc Physicians India; 2022 Aug; 70(8):11-12. PubMed ID: 36082725
[TBL] [Abstract][Full Text] [Related]
12. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
[TBL] [Abstract][Full Text] [Related]
13. The role of tubulointerstitial markers in differential diagnosis and prognosis in patients with type 2 diabetes and biopsy proven diabetic kidney disease.
Wang X; Ren L; Huang Y; Feng Z; Zhang G; Dai H
Clin Chim Acta; 2023 Jul; 547():117448. PubMed ID: 37331550
[TBL] [Abstract][Full Text] [Related]
14. Severe 25-Hydroxyvitamin D Deficiency May Predict Poor Renal Outcomes in Patients With Biopsy-Proven Diabetic Nephropathy.
Zhou T; Shen L; Li Z; Jia J; Xing H; Wang N; Jiao Q; Fan Y
Front Endocrinol (Lausanne); 2022; 13():871571. PubMed ID: 35600603
[TBL] [Abstract][Full Text] [Related]
15. Histologic predictors of renal outcome in diabetic nephropathy: Beyond renal pathology society classification.
Stefan G; Stancu S; Zugravu A; Petre N; Mandache E; Mircescu G
Medicine (Baltimore); 2019 Jul; 98(27):e16333. PubMed ID: 31277183
[TBL] [Abstract][Full Text] [Related]
16. Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.
Dande RR; Peev V; Altintas MM; Reiser J
J Diabetes Res; 2017; 2017():3232848. PubMed ID: 28596971
[TBL] [Abstract][Full Text] [Related]
17. The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study.
Li R; Xie Z; Zhang L; Huang Y; Ma J; Dong W; Li Z; Chen Y; Liang H; Wu Y; Zhao X; Wang W; Ye Z; Liu S; Shi W; Liang X
Ren Fail; 2021 Dec; 43(1):452-459. PubMed ID: 33657976
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy.
Mise K; Hoshino J; Ueno T; Hazue R; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Fujii T; Hara S; Ohashi K; Takaichi K; Ubara Y
Diabetes Metab Res Rev; 2015 Sep; 31(6):572-81. PubMed ID: 25533683
[TBL] [Abstract][Full Text] [Related]
19. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
[TBL] [Abstract][Full Text] [Related]
20. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
